ASXL-Related Disorders Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03303716

Recruitment Status : Recruiting

First Posted : October 6, 2017

Last Update Posted : December 1, 2022

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Boston Children's Hospital

Children's Hospital Medical Center, Cincinnati

Duke University

Information provided by (Responsible Party):

Bianca E. Russell, MD, University of California, Los Angeles

Study Description

Brief Summary:

A registry focused on the natural history, management and treatment of patients with Bohring-Opitz Syndrome (ASXL1), Shashi-Pena Syndrome (ASXL2) and Bainbridge-Ropers Syndrome (ASXL3).

Condition or disease
Bohring-Opitz Syndrome ASXL1 Gene Mutation Shashi-Pena Syndrome ASXL2 Gene Mutation Bainbridge-Ropers Syndrome ASXL3 Gene Mutation

Detailed Description:

Study participants will be asked to complete a series of brief surveys over time about their medical condition. The researchers will also attain primary medical records.The registry is based at UCLA as the IRB of record with collaborating sites at Boston Children's Hospital, Cincinnati Children's Hospital, and Duke University in a partnership with the Bohring-Opitz Syndrome (BOS) Foundation and ASXL-Rare Research Endowment (ARRE). The BOS Foundation and ARRE are non-profit organizations run by families of patients with ASXL-related disorders that are focused on supporting research. The data is co-managed by the researchers and the family groups. Aggregate data from the Registry will be shared with the participants as well as used for publication. The Registry is HIPPA compliant and follows all the IRB requirements regarding securing and managing patient data.

Study Design

Layout table for study information

Study Type :	Observational [Patient Registry]
Estimated Enrollment :	200 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Target Follow-Up Duration:	20 Years
Official Title:	Clinical Registry for ASXL-Related Disorders and Disorders of Chromatin Remodeling
Actual Study Start Date :	September 20, 2017
Estimated Primary Completion Date :	September 2037
Estimated Study Completion Date :	September 2037

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Bohring-Opitz syndrome

Genetic and Rare Diseases Information Center resources: Bohring-Opitz Syndrome Bainbridge-Ropers Syndrome Shashi-Pena Syndrome

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

Natural history, treatment and management strategies of ASXL-related disorders [ Time Frame: 20 years ]
Use participant surveys including the GRDR CDE standard questions to collect data on disease history and management. Attain primary medical records with goal of publications to enhance treatment, management and understanding of the natural history of ASXL gene disorders.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

All patients with molecularly proven or suspected ASXL related disorders

Criteria

Inclusion Criteria:

Clinical or molecular diagnosis of an ASXL related disorder

Exclusion Criteria:

No clinical or molecular diagnosis of an ASXL related disorder

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03303716

Contacts

Layout table for location contacts

Contact: Bianca Russell, MD	(310) 206-6581	ASXL-CHROMATIN-REGISTRY@mednet.ucla.edu

Locations

Layout table for location information

United States, California
University of California, Los Angeles	Recruiting
Los Angeles, California, United States, 90095
Contact: Bianca Russell, MD 310-206-6581 ASXL-CHROMATIN-REGISTRY@mednet.ucla.edu

Sponsors and Collaborators

University of California, Los Angeles

Boston Children's Hospital

Children's Hospital Medical Center, Cincinnati

Duke University

Investigators

Layout table for investigator information

Principal Investigator:	Wen-Hann Tan, BMBS	Boston Children's Hospital
Principal Investigator:	Loren Pena, MD, PhD	Children's Hospital Medical Center, Cincinnati
Principal Investigator:	Vandana Shashi, MD, PhD	Duke University
Principal Investigator:	Bianca Russell, MD	University of California, Los Angeles

More Information

Additional Information:

Layout table for additonal information

Responsible Party:	Bianca E. Russell, MD, Bianca Russell, MD, University of California, Los Angeles
ClinicalTrials.gov Identifier:	NCT03303716
Other Study ID Numbers:	CIN_ASXLRegistry_001
First Posted:	October 6, 2017 Key Record Dates
Last Update Posted:	December 1, 2022
Last Verified:	November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Additional relevant MeSH terms:

Layout table for MeSH terms

Syndrome Disease Pathologic Processes

To Top